Technical Feasibility Evaluation of Mucosal Staining During Colon Capsule Endoscopy (CCE) Procedure in Colorectal Cancer (CRC) High Risk Population, When Using MB-MMX

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

September 28, 2022

Study Completion Date

September 28, 2022

Conditions
Colorectal CancerPolyp, Colonic
Interventions
DEVICE

PillCam Colon2 procedure with MB-MMX

Subjects will undergo a bowel preparation (single dose, 4L PEG), including 200 mg Methylthioninium chloride, corresponding to eight 25 mg MB-MMX tablets and 1 tab of Resolor (Prucalopride 1mg). An experienced Gastroenterologist will read the CCE procedure and complete a subjective questionnaire, to evaluate mucosal enhancement during a CCE procedure, when using MB-MMX as a contrast-enhancement technique.

Trial Locations (1)

31008

Complejo Hospitalario de Navarra, Pamplona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Medtronic - MITG

INDUSTRY

NCT05022719 - Technical Feasibility Evaluation of Mucosal Staining During Colon Capsule Endoscopy (CCE) Procedure in Colorectal Cancer (CRC) High Risk Population, When Using MB-MMX | Biotech Hunter | Biotech Hunter